(isatuximab) Phase 3 trial met primary endpoint of progression free survival in patie | IMGN Message Board Posts


IMGN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  57274 of 57658  at  12/7/2023 8:49:04 AM  by

very

The following message was updated on 12/7/2023 8:51:04 AM.

(isatuximab) Phase 3 trial met primary endpoint of progression free survival in patie

https://finance.yahoo.com/news/press-release-sarclisa-isatuximab-phase-063500551.html

licensed from IMGN

(isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 3  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
57275 Re: (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patie GaryM 0 12/7/2023 12:22:38 PM
57277 Re: (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patie GaryM 0 12/7/2023 2:26:30 PM




Financial Market Data provided by
.
Loading...